Tenaya Therapeutics Inc Share Price Today: Live Updates & Key Insights

Tenaya Therapeutics Inc share price today is $0.7515, up -6.53%. The stock opened at $0.79 against the previous close of $0.8037, with an intraday high of $0.8315 and low of $0.7506.

Tenaya Therapeutics Inc Share Price Chart

Tenaya Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Tenaya Therapeutics Inc Share Price Performance

$0.7515 -0.0653(-6.53%) TNYA at 23 Mar 2026 03:32 PM Biotechnology
Lowest Today 0.7506
Highest Today 0.8315
Today’s Open 0.79
Prev. Close 0.8037
52 Week High 2.35
52 Week Low 0.36
Day’s Range: Low 0.7506 High 0.8315
52-Week Range: Low 0.36 High 2.35
1 day return -
1 Week return -11.61
1 month return +27.25
3 month return +0.21
6 month return -46.15
1 year return +8.21
3 year return -71.32
5 year return -95.26
10 year return -

Tenaya Therapeutics Inc Institutional Holdings

Column Group LLC 4.34

Vanguard Group Inc 3.95

Vanguard Total Stock Mkt Idx Inv 2.99

Millennium Management LLC 2.13

Citadel Advisors Llc 1.94

Anson Funds Management LP 1.92

Alyeska Investment Group, L.P. 1.85

BlackRock Inc 1.07

Burkehill Global Management, LP 0.92

Kalehua Capital Management LLC 0.92

Renaissance Technologies Corp 0.85

ADAR1 Capital Management LLC 0.69

Sphera Funds Management Ltd. 0.69

GSA Capital Partners LLP 0.68

iShares Biotechnology ETF 0.68

Marshall Wace Asset Management Ltd 0.65

Two Sigma Investments LLC 0.58

Geode Capital Management, LLC 0.55

Vanguard Institutional Extnd Mkt Idx Tr 0.51

Euclidean Capital LLC 0.47

Alphabet Inc 0.42

Raiffeisen Bank International AG 0.42

Raiffeisen-Health&Wellbeing-ESG Akt A 0.42

Jane Street Group LLC 0.31

Fidelity Extended Market Index 0.25

Blackrock Extended Mkt Fund CF 0.16

Extended Equity Market Fund K 0.14

Fidelity Total Market Index 0.08

Bridgeway Ultra-Small Company Market 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.08

Vifag 2002 SICAV 0.07

Fidelity Series Total Market Index 0.07

Spartan Extended Market Index Pool F 0.06

Fidelity Nasdaq Composite Index 0.06

NT Ext Equity Mkt Idx Fd - NL 0.05

Vanguard Balanced Index Inv 0.05

iShares Nasdaq US Biotech ETF USD Acc 0.05

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

Tenaya Therapeutics Inc Market Status

Strong Buy: 6

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Tenaya Therapeutics Inc Fundamentals

Market Cap 163.01 M

PB Ratio 1.3223

PE Ratio 0.0

Enterprise Value 73.28 M

Total Assets 146.92 M

Volume 4148491

Tenaya Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-127665000 -127.7M, FY22:-123663044 -123.7M, FY21:-69652000 -69.7M, FY20:-38308000 -38.3M, FY19:-25778000 -25.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-1864000 -1.9M, Q2/2025:-2084000 -2.1M, Q1/2025:null 0.0M, Q3/2024:null 0.0M, Q2/2024:-2123000 -2.1M

Quarterly Net worth Q3/2025:-20275000 -20.3M, Q2/2025:-23283000 -23.3M, Q1/2025:-26864000 -26.9M, Q3/2024:-25634000 -25.6M, Q2/2024:-29431000 -29.4M

About Tenaya Therapeutics Inc & investment objective

Company Information Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Organisation Biotechnology

Employees 70

Industry Biotechnology

CEO Mr. Faraz Ali M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Tenaya Therapeutics Inc FAQs

What is the share price of Tenaya Therapeutics Inc today?

The current share price of Tenaya Therapeutics Inc is $0.7515.

Can I buy Tenaya Therapeutics Inc shares in India?

Yes, Indian investors can buy Tenaya Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Tenaya Therapeutics Inc shares in India?

You can easily invest in Tenaya Therapeutics Inc shares from India by:

Can I buy fractional shares of Tenaya Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Tenaya Therapeutics Inc?

Tenaya Therapeutics Inc has a market cap of $163.01 M.

In which sector does Tenaya Therapeutics Inc belong?

Tenaya Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Tenaya Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Tenaya Therapeutics Inc?

The PE ratio of Tenaya Therapeutics Inc is N/A and the PB ratio is 1.32.